A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...

Optometrist Amy Green discussed the importance of OCT in identifying AMD cases during the AOP’s Locum Clinical Skills ...

As we age, our vision undergoes natural changes, including difficulty focusing on near objects (presbyopia) and reduced light ...

Though new to Brevard County, Dr. Peter Bracha brings more than a decade of experience treating the full range of retinal conditions.

(Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen ...